p63 transcriptional regulation of epithelial integrity and cancer

Cell Cycle

Volumn 6, Issue 3, 2007, Pages 240-245

  Trink, Barry ^a   Osada, Motonobu ^a   Ratovitski, Edward ^a   Sidransky, David ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer; Downstream targets; p53; p63; p73; Transcription

Indexed keywords

BETA CATENIN; PROTEIN P53; PROTEIN P63;

APOPTOSIS; CANCER; CARCINOGENESIS; CELL ADHESION; CELL CYCLE ARREST; CELL DIFFERENTIATION; CELL FUNCTION; DNA BINDING; DOWNSTREAM PROCESSING; EPITHELIUM; GENE ACTIVATION; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE TARGETING; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN DOMAIN; REVIEW; RNA PROCESSING; TRANSCRIPTION REGULATION;

EID: 33847009873     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.6.3.3803     Document Type: Review

References (63)

1. Barbieri C, Tang L, Brown K, Pietenpol J. Loss of p63 leads to increased cell migration and up-regulation of genes involved in invasion and metastasis. Cancer Res 2006; 66:7589-97.
2. Brachat A, Pierrat B, Xynos A, Brecht K, Simonen M, Brungger A, Heim J. A microarray-based, integrated approach to identify novel regulators of cancer drug response and apoptosis. Oncogene 2002; 21:8361-71.
3. Candi E, Rufini A, Terrinoni A, Dinsdale D, Ranalli M, Paradisi A, De Laurenzi V, Spagnoli L, Catani M, Ramadan S, Knight R, Melino G. Differential roles of p63 isoforms in epidermal development: selective genetic complementation in p63 null mice. Cell Death Differ 2006; 13:1037-47.
4. Candi E, Terrinoni A, Rufini A, Chikh A, Lena A, Suzuki Y, Sayan B, Knight R, Melino G. p63 is upstream of IKKα in epidermal development. J Cell Sci 2006; 119:4617-22.
5. Carroll D, Carroll J, Leong C, Cheng F, Brown M, Mills A, Brugge J, Ellisen L. p63 regulates an adhesion programme and cell survival in epithelial cells. Nat Cell Biol 2006; 8:551-61.
6. Celli J, Duijf P, Hamel BC, Bamshad M, Kramer B, Smits A, Newbury-Ecob R, Hennekam R, Van Buggenhout G, van Haeringen A, Woods C, van Essen A, de Waal R, Vriend G, Haber D, Yang A, McKeon F, Brunner H, van Bokhoven H. Heterozygous germline mutations in the p53 homolog p63 are the cause of EEC syndrome. Cell 1999; 99:143-53.
7. Dai X, Segre J. Transcriptional control of epidermal specification and differentiation. Curr Opin Genet Dev 2004; 14:485-91.
8. Deyoung M, Johannessen C, Leong C, Faquin W, Rocco J, Ellisen L. Tumor-specific p73 up-regulation mediates p63 dependence in squamous cell carcinoma. Cancer Res 2006; 66:9362-68.
9. Dohn M, Zhang S, Chen X. p63α and ΔNp63α can induce cell cycle arrest and apoptosis and differentially regulate p53 target genes. Oncogene 2001; 20:3193-3205.
10. Ellisen L, Ramsayer K, Johannessen C, Yang A, Beppu H, Minda K, Oliner J, McKeon F, Haber D. REDD1, a developmentally regulated transcriptional target of p63 and p53, links p63 to regulation of reactive oxygen species. Mol Cell 2002; 10:995-1005.
11. Flores E, Sengupta S, Miller J, Newman J, Bronson R, Crowley D, Yang A, McKeon F, Jacks T. Tumor predisposition in mice mutant for p63 and p73: evidence for broader tumor suppressor functions for the p53 family. Cancer Cell 2005; 7:363-73.
12. Fomenkov A, Huang Y, Topaloglu O, Brechman A, Osada M, Fomenkova T, Yuriditsky E, Trink B, Sidransky D, Ratovitski E. P63α mutations lead to aberrant splicing of keratinocyte growth factor receptor in the Hay-Wells syndrome. J Biol Chem 2003; 278:23906-14.
13. Fontemaggi G, Kela I, Amariglio N, Rechavi G, Krishnamurthy J, Strano S, Sacchi A, Givol D, Blandino G. Identification of direct p73 target genes combining DNA microarray and chromatin immunoprecipitation analyses. J Biol Chem 2002; 277:43359-68.
14. Gressner O, Schilling T, Lorenz K, Schulze Schleithoff E, Koch A, Schulze-Bergkamen H, Maria Lena A, Candi E, Terrinoni A, Valeria Catani M, Oren M, Melino G, Krammer P, Stremmel W, Muller M. TAp63α induces apoptosis by activating signaling via death receptors and mitochondria. EMBO J 2005; 24:2458-71
15. Hagiwara K, McMenamin M, Miura K, Harris C. Mutational analysis of the p63/p73L/p51/p40/CUSP/KET gene in human cancer cell lines using intronic primers. Cancer Res 1999; 59:4165-69.
16. Helton E, Zhu J, Chen X. The unique NH2-terminally deleted (ΔN) residues, the PXXP motif, and the PPXY motif are required for the transcriptional activity of the ΔN variant of p63. J Biol Chem 2006; 281:2533-42.
17. Hibi K, Trink B, Patturajan M, Westra W, Caballero O, Hill D, Ratovitski E, Jen J, Sidransky D. AIS is an oncogene amplified in squamous cell carcinoma. Proc Natl Acad Sci USA 2000; 97:5462-67.
18. Ihrie R, Marques M, Nguyen B, Horner J, Papazoglu C, Bronson R, Mills A, Attardi L. Perp is a p63-regulated gene essential for epithelial integrity. Cell 2005; 120:843-56.
19. Inga A, Storici F, Darden T, Resnick M. Differential transactivation by the p53 transcription factor is highly dependent on p53 level and promoter target sequence. Mol Cell Biol 2002; 22:8612-25
20. Kannan K, Amariglio N, Rechavi G, Jakob-Hirsch J, Kela I, Kaminski N, Getz G, Domany E, Givol D. DNA microarrays identification of primary and secondary target genes regulated by p53. Oncogene 2001; 20:2225-34.
21. Keyes W, Vogel H, Koster M, Guo X, Qi Y, Petherbridge K, Roop , Bradley A, Mills A. p63 heterozygous mutant mice are not prone to spontaneous or chemically induced tumors. Proc Natl Acad Sci USA 2006; 103:8435-40.
22. King K, Ponnamperuma R, Yamashita T, Tokino T, Lee L, Young M, Weinberg W. ΔNp63α functions as both a positive and a negative transcriptional regulator and blocks in vitro differentiation of murine keratinocytes. Oncogene 2003; 22:3635-44.
23. Kommagani R, Caserta T, Kadakia M. Identification of vitamin D receptor as a target of p63. Oncogene 2006; 25:3745-51.
24. Kurata S, Okuyama T, Osada M, Watanabe T, Tomimori Y, Sato S, Iwai A, Tsuji T, Ikawa Y, Katoh I. p51/p63 Controls subunit α3 of the major epidermis integrin anchoring the stem cells to the niche. J Biol Chem 2004; 279:50069-77.
25. Laurikkala J, Mikkola M, James M, Tummers M, Mills A, Thesleff I. p63 regulates multiple signalling pathways required for ectodermal organogenesis and differentiation. Development 2006; 133:1553-63.
26. Maatta A, DiColandrea T, Groot K, Watt F. Gene targeting of envoplakin, a cytoskeletal linker protein and precursor of the epidermal cornified envelope. Mol Cell Biol 2001; 21:7047-53.
27. McGrath J, Duijf P, Doetsch V, Irvine A, de Waal R, Vanmolkot K, Wessagowit V, Kelly A, Atherton D, Griffiths W, Orlow S, van Haeringen A, Ausems M, Yang A, McKeon F, Bamshad M, Brunner H, Hamel B, van Bokhoven H. Hay-Wells syndrome is caused by heterozygous missense mutations in the SAM domain of p63. Hum Mol Genet 2001; 10:221-29.
28. McKeon F. p63 and the epithelial stem cell: more than status quo? Genes Dev 2004; 18:465-69.
29. Massion P, Taflan P, Jamshedur Rahman S, Yildiz P, Shyr Y, Edgerton M, Westfall M, Roberts J, Pietenpol J, Carbone D, Gonzalez A. Significance of p63 amplification and overexpression in lung cancer development and prognosis. Cancer Res 2003; 63:7113-21.
30. Mills A, Zheng B, Wang X, Vogel H, Roop D, Bradley A. p63 is a p53 homologue required for limb and epidermal morphogenesis. Nature 1999; 398:708-13.
31. Mills A. p63: oncogene or tumor suppressor? Curr Opin Genet Dev. 2006; 16:38-44
32. Nakagawa T, Takahashi M, Ozaki T, Watanabe Ki K, Todo S, Mizuguchi H, Hayakawa T, Nakagawara A. Autoinhibitory regulation of p73 by ΔNp73 to modulate cell survival and death through a p73-specific target element within the ΔNp73 promoter. Mol Cell Biol 2002; 22:2575-85.
33. Ortt K, Sinha S. Derivation of the consensus DNA-binding sequence for p63 reveals unique requirements that are distinct from p53. FEBS Lett 2006; 580:4544-50.
34. Osada M, Ohba M, Kawahara C, Ishioka C, Kanamaru R, Katoh I, Ikawa Y, Nimura Y, Nakagawara A, Obinata M, Ikawa S. Cloning and functional analysis of human p51, which structurally and functionally resembles p53. Nat Med 1998; 4:839-43.
35. Osada M, Nagakawa Y, Park H, Yamashita K, Wu G, Kim M, Fomenkov A, Trink B, Sidransky D. p63-specific activation of the BPAG-1e promoter. J Invest Dermatol 2005; 125:52-60.
36. Osada M, Park H, Nagakawa Y, Yamashita K, Fomenkov A, Kim M, Wu G, Nomoto S, Trink B, Sidransky D. Differential recognition of response elements determines target gene specificity for p53 and p63. Mol Cell Biol 2005; 25:6077-89.
37. Osada M, Park H, Nagakawa Y, Begum S, Yamashita K, Wu G, Kim M, Trink B, Sidransky D. A novel response element confers p63- and p73-specific activation of the WNT4 promoter. Biochem Biophys Res Commun 2006; 339:1120-28.
38. Parsa R, Yang A, McKeon F, Green H. Association of p63 with proliferative potential in normal and neoplastic human keratinocytes. J Invest Dermatol 1999; 113:1099-1105.
39. Patturajan M, Nomoto S, Sommer M, Fomenkov A, Hibi K, Zangen R, Poliak N, Califano J, Trink B, Ratovitski E, Sidransky D. ΔNp63 induces β-catenin nuclear accumulation and signaling. Cancer Cell 2002; 1:369-79.
40. Pietenpol J, Tokino T, Thiagalingam S, el-Deiry W, Kinzler K, Vogelstein B. Sequence-specific transcriptional activation is essential for growth suppression by p53. Proc Natl Acad Sci USA 1994; 91:1998-2002
41. Ratovitski E, Trink B, Sidransky D. p63 and p73: teammates or adversaries? Cancer Cell. 2006; 9:1-2.
42. Rocco J, Leong C, Kuperwasser N, DeYoung M, Ellisen L. p63 mediates survival in squamous cell carcinoma by suppression of p73-dependent apoptosis. Cancer Cell 2006; 9:45-56.
43. Sasaki Y, Ishida S, Morimoto I, Yamashita T, Kojima T, Kihara C, Tanaka T, Imai K, Nakamura Y, Tokino T. The p53 family member genes are involved in the Notch signal pathway. J Biol Chem 2002; 277:719-24.
44. Sasaki Y, Mita H, Toyota M, Ishida S, Morimoto I, Yamashita T, Tanaka T, Imai K, Nakamura Y, Tokino T. Identification of the interleukin 4 receptor α gene as a direct target for p73. Cancer Res 2003; 63:8145-52.
45. Sasaki Y, Naishiro Y, Oshima Y, Imai K, Nakamura Y, Tokino T. Identification of pigment epithelium-derived factor as a direct target of the p53 family member genes. Oncogene 2005; 24:5131-36.
46. Strano S, Monti O, Pediconi N, Baccarini A, Fontemaggi G, Lapi E, Mantovani F, Damalas A, Citro G, Sacchi A, Del Sal G, Levrero M, Blandino G. The transcriptional coactivator Yes-associated protein drives p73 gene-target specificity in response to DNA Damage. Mol Cell 2005; 18:447-59.
47. Tokino T, Thiagalingam S, el-Deiry W, Waldman T, Kinzler K, Vogelstein B. p53 tagged sites from human genomic DNA. Hum Mol Genet 1994; 3:1537-42.
48. Trink B, Okami K, Wu L, Sriuranpong V, Jen J, Sidransky D. A new human p53 homologue. Nat Med 1998; 4:747-48.
49. Truong A, Kretz M, Ridky T, Kimmel R, Khavari P.p63 regulates prolilferation and differentiation of developmentally mature keratinocytes. Genes & Dev. 2006; 20:3185-97
50. Uitto J., Christiano A. Molecular genetics of the cutaneous basement membrane zone. Perspectives on epidermolysis bullosa and other blistering skin diseases J. Clin Invest 1992; 90:687-92.
51. Vigano M, Lamartine J, Testoni B, Merico D, Alotto D, Castagnoli C, Robert A, Candi E, Melino G, Gidrol X, Mantovani R. New p63 targets in keratinocytes identified by a genome-wide approach. EMBO J 2006; 25:5105-16.
52. Yang A, Kaghad M, Wang Y, Gillett E, Fleming M, Dotsch V, Andrews N, Caput D, McKeon F. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell 1998; 2:305-16.
53. Yang A, Schweitzer R, Sun D, Kaghad M, Walker N, Bronson R, Tabin C, Sharpe A, Caput D, Crum C, McKeon F. p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature 1999; 398:714-18.
54. Yarnell A, Oh S, Reinberg D, Lippard S. Interaction of FACT, SSRP1, and the high mobility group (HMG) domain of SSRP1 with DNA damaged by the anticancer drug cisplatin. J Biol Chem 2001; 276:25736-41.
55. Yu J, Zhang L, Hwang P. Rago C, Kinzler K, Vogelstein B. Identification and classification of p53-regulated genes. Proc Natl Acad Sci USA 2000; 96:14517-22.
56. Westfall M, Mays D, Sniezek J, Pietenpol J. The ΔNp63α phosphoprotein binds the p21 and 14-3-3σ promoters in vivo and has transcriptional repressor activity that is reduced by Hay-Wells syndrome-derived mutations. Mol Cell Biol 2003; 23:2264-76.
57. Wu G, Nomoto S, Hoque MO, Dracheva T, Osada M, Lee CC, Dong S, Guo Z, Benoit N, Cohen Y, Rechthand P, Califano J, Moon C, Ratovitski E, Jen J, Sidransky D, Trink B. ΔNp63α and TAp63α regulate transcription of genes with distinct biological functions in cancer and development. Cancer Res 2003; 63:2351-7235.
58. Wu G, Osada M, Guo Z, Fomenkov A, Begum S, Zhao M, Upadhyay S, Xing M, Wu F, Moon C, Westra W, Koch W, Mantovani R, Califano J, Ratovitski E, Sidransky D, Trink B. ΔNp63α up-regulates the Hsp70 gene in human cancer. Cancer Res 2005; 65:758-66.
59. Zangen R, Ratovitski E, Sidransky D. ΔNp63α levels correlate with clinical tumor response to cisplatin. Cell Cycle 2005; 4:1313-15.
60. Zembutsu H, Ohnishi Y, Tsunoda T, Furukawa Y, Katagiri T, Ueyama Y, Tamaoki N, Nomura T, Kitahara O, Yanagawa R, Hirata K, Nakamura Y. Genome-wide cDNA microarray screening to correlate gene expression profiles with sensitivity of 85 human cancer xenografts to anticancer drugs. Cancer Res 2002; 62:518-27.
61. Zeng S, Dai M, Keller D, Lu H. SSRP1 functions as a co-activator of the transcriptional activator p63. EMBO J 2002; 21:5487-97.
62. Zhao R, Gish K, Murphy M, Yin Y, Notterman D, Hoffman W, Tom E, Mack D, Levine A. Analysis of p53-regulated gene expression patterns using oligonucleotide arrays. Genes Dev 2000; 14:981-93.
63. Zheng X, Chen X. Aquaporin 3, a glycerol and water transporter is regulated by p73 of the p53 family. FEBS Lett 2001; 489:4-7.